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Abstract
Acute pancreatitis is a potentially life-threatening disease. If the diagnosis and the treatment are not prompt, it can rapidly evolve
to a medical emergency. Severe hypertriglyceridemia, deﬁned as above 1000 mg/dl, is the third most common cause of acute pan-
creatitis. Conventional management includes fat dietary restriction and pharmacological treatment; however, these measures take
time to be effective. Plasmapheresis seems to be an alternative and safe adjunctive therapy because it allows the rapid reduction of
the trigger agent in circulation. Its use, especially in severe cases, has been increasingly reported. The authors report three cases of
severe hypertriglyceridemia-induced pancreatitis in which early plasmapheresis was successfully used with other supportive clin-
ical management.
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Introduction
Acute pancreatitis (AP) is a potentially life-threatening dis-
ease. Without prompt diagnosis and treatment, it can rapidly
evolve to a medical emergency, leading into pancreatic necro-
sis and ultimately to death (1, 2). Serum hypertriglyceridemia
(HTG) is the third most frequent cause of AP after gallstones
and alcohol, with a reported incidence of 1%–10% (3). Serum
triglyceride levels >1000mg/dl, also known as severe hypertri-
glyceridemia (SHTG), are usually needed to trigger AP (4–6).
Conventional management of SHTG includes fat dietary
restriction and pharmacological treatment; however, the
slow action of antihyperlipidemic therapy poses a problem
when the situation requires a rapid reduction of the offending
agent in circulation (2). Plasmapheresis (PF) seems to be an
alternative and safe therapy for these kinds of cases because
it allows the rapid reduction of triglycerides (TG) in just
a few hours (7, 8). Its use, especially in high-risk patients
admitted in intensive care units, has been increasingly
reported. Unfortunately, there are no controlled or rando-
mized studies to prove its beneﬁt in mortality reduction.
Most of the data are based on single case reports. That is
why the American Society for Apheresis (ASFA) recommen-
dation for this indication is only Grade 2C (9). PF does not
interfere in TG production, and therefore, it should always
be considered as an adjunctive therapy to medical treatment.
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In our hospital, PF is a technique performed by nephrolo-
gists, regardless of whether the indication is nephrologic
or not.
Due to the importance of describing all new cases, the
authors report three cases of SHTG-induced AP in which
early PF was used with other supportive clinical management.
Case Reports
The patients were admitted to the emergency department
with an AP; the etiology factor identiﬁed was SHTG. All of
them had an unfavorable course under medical management
in the ﬁrst 24–48 h. There was no previous available lipid pro-
ﬁle, history of treatment with cholesterol or TG-lowering
drugs, or history of gallstones or relevant family history. PF
was done according to TG levels. A temporary central venous
catheter was placed with no complications. A double mem-
brane ﬁltration device and 5% albumin as the replacement
ﬂuid were used. The volume treated was correspondent to
one plasma volume and the duration of the session was
according to the replacement. Nonfractioned heparin was
used for anticoagulation. There were no PF-related complica-
tions. At discharge, the patients were medicated with lower
lipid drugs. At follow-up, as an outpatient, all of them were
asymptomatic and their TG and pancreatic enzyme levels
were within the normal range.
To clarify, data in Table 1 refer to variables at admission.
In Figure 1, it is represented as the effect of PF on serum TG.
Case 1
This is a case of a 43-year-old male with type 2 diabetes diag-
nosed 6 years before, with poor metabolic control, dyslipide-
mia, and obesity (body mass index (BMI): 30.6 kg/m2). He
had no history of gallstones or alcohol intake. He was
admitted with an epigastric abdominal pain with dorsal irra-
diation, nausea, and vomiting that begun 24 h before. On
examination, he had no fever, pulse rate was 124/min, and
blood pressure was 100/60 mm Hg. He was prostrate and
with signs of dehydration. The abdomen was diffusely
Table 1. Initial laboratory data of patients prior to the plasmapheresis treatment
Laboratory ﬁndings Case 1 Case 2 Case 3 Reference values
Hemoglobin (g/dl) 16 17 16.6 13–18
Hematocrit (%) 40 38 42 40–52
Platelets/mm3 287,000 151,000 201,000 150–440
Total leucocyte count/μL 17670 14290 5850 3800–10600
CRP (mg/dl) 327.65 56.5 337 <5.0
Amylase (U/L) 663 1033 70 <3.0
Lipase (U/L) 2686 750 2485 13–60
Triglycerides (mg/dl) 1229 5565 1348 <200
Total cholesterol (mg/dl) 630 750 350 <200
AST/ALT (mg/dl) 50/26 109/72 67/91 4–50/4–33
Total bilirubin/direct bilirubin (mg/dl) 0.7/0.1 0.9/0.2 1.0/0.1 0.1–1.1; 0.1–0.3
Sodium (mmol/L) 122 128 135 135–145
Calcium (mg/dl) 9.0 8.7 8.8 8.8–10.2
Glucose (mg/dl) 575 >400 180 60–100
Lactate desidrogenase (U/L) 474 370 259 135–225
Creatinine (mg/dl) 1.96 0.71 1.7 0.67–1.17
Urea (mg/dl) 65 28 29 15–45
Bicarbonate (mmol/L) 12 16 17 22–26
Lactates 5.0 2 2.6
HbA1C (%) 11.6 12 11 <7.0
AST, aspartate transaminase/ALT, alanine transaminase; CRP, C-reactive protein.
Codon Publications Journal of Renal and Hepatic Disorders 2017; 1(1): 29–34 30
Campos A et al.
painful. He was oliguric. There were no other abnormalities.
Laboratory tests showed leukocytosis and neutrophilia, an
elevated C-reactive protein (CRP), a diabetic ketoacidosis,
hyperlactacidemia; pancreatic alpha-amylase 663 mg/dl,
lipase 2686 mg/dl; and TG 1229 (Table 1). Abdominal com-
puted tomography (CT) showed a gallbladder without chole-
cystitis or lithiasis, pancreas with necrosis (~90%), and a
necro-hemorrhagic collection in the tail. Delayed renal excre-
tion of iodinated contrast was observed. Microbiological
cultures were negative. The patient started on a fasting regi-
men, and treatment began with endovenous ﬂuids and insulin.
The initial response was unfavorable, with sustained hemo‐
dynamic instability, respiratory distress, and oliguria. He
was admitted to the intensive care unit with Acute Physiology
and Chronic Health Evaluation II (APACHE II) score 14
with need of hemodynamic and respiratory support. TG
and lipase increased in the ﬁrst 24 h and renal function wor-
sened (creatinine 4.96 mg/dl). He was submitted to an urgent
PF on day 2 of admission. The TG decreased to <1000 mg/dl
and 248 mg/dl after the ﬁrst and second sessions of PF, respec-
tively; the pancreatic enzymes normalized. The patient
showed signiﬁcant clinical improvement with resolution of
multiorgan dysfunction, namely, renal dysfunction. He was
started on oral fat-free diet and fenoﬁbrate on day 4 and dis-
charged from the intensive care unit to the surgery department
on day 10. ACT follow-up at 72 h showed a regression of pan-
creas necrosis and of hemorrhagic collection, with no signs of
infection. A revaluation CT scan was done 2 weeks after
showing a complete recovery of pancreatic necrosis. Fortu-
nately, he did not present any late complications of this severe
pancreatitis, including acute ﬂuid collections, pancreatic
necrosis pseudocysts, abscesses, ascitis and pancreatic ﬁstulas,
splenic vein thrombosis, or false aneurysms. On follow-up
after 2 months, his TG levels were found normal.
Case 2
This is a case of a 42-year-old manwith type 2 diabetes, hyper-
tension, obesity (BMI 41.5 kg/m2), and a past history of
dyslipidemia. He had a schizophrenia and the therapeutic
compliance was very poor. He was admitted with a diffuse
abdominal pain. On physical examination at admission, he
had no fever and was hemodynamically stable. The abdom-
inal examination showed tenderness in the right upper quad-
rant, with no other abnormalities. Respiratory, cardiovascular,
and neurologic examinations were unremarkable.
Laboratory studies at admission showed leukocytosis with
neutrophilia, an elevated CRP, and a severe hypertriglyceri-
demia (TG 5565 mg/dl). Other relevant laboratory results at
admission and in posterior workup are presented in Table 1.
The abdominal CT showed an acute nonlithiasic edematous
pancreatitis.
The patient was admitted to the intermediate care unit with
APACHE II score 10, and started on a fasting regimen, insu-
lin perfusion, and ﬂuids. In the context of severe pancreatitis
and vigorous ﬂuid therapy, he developed signs of heart failure
in the ﬁrst 48 h, requiring oxygen and diuretic therapy. Trans-
thoracic echocardiography did not show any abnormalities.
The abdominal pain and the pancreatic markers worsened.
In the absence of response to medical therapy during the
ﬁrst 48 h, he started on PF treatment. He needed two conse-
cutive sessions. The procedure was complicated by the clot-
ting of the ﬁlters due to the high plasma viscosity requiring
high doses of unfractionated heparin. After the ﬁrst session,
his TG levels were 826 mg/dl. One additional PF session
was performed in the subsequent day (Figure 1). A complete
clinical and analytical recovery was seen on the patient.
Case 3
A 38-year-old male with uncontrolled type 2 diabetes and a
known history of high alcohol consumption (>200 g/day)
was admitted to the emergency room with an epigastric
pain and nausea. On examination, he was hemodynamically
stable. Respiratory and cardiovascular examinations were
normal. He presented with abdominal pain and distention.
Laboratory tests at admission are shown in Table 1. The
abdominal CT showed aspects of AP without dilation of the
bile ducts or gallstones.
The blood was highly lipemic and on ultracentrifuge
showed TG 1348mg/dl. The patient was admitted to the inter-
mediate care unit, with APACHE II score 8. He was initially
managed with fasting, glucose control, and enteral ﬁbrate.
Despite the medical management, 24 h after admission,
there was a lack of improvement; the renal function worsened
with serum creatinine/urea (2.5/85 mg/dl). Therefore, we
started PF. He underwent two sessions in consecutive days
with clinical, analytical, and imagological improvements.
The patient was discharged 7 days after admission with
oral atorvastatin, fenoﬁbrate, and insulin.
Discussion and Conclusions
AP could be a medical emergency associated with higher
morbidity and mortality. Due to potential associated
TG (admission) PF 1 PF 2
Case 1 1229 760 248
Case 2 5565 826 557
Case 3 1348 410
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Figure 1. Effect of plasmapheresis on serum triglycerides
(TG). PF1: TG after ﬁrst plasmapheresis treatment; PF2:
TG after second plasmapheresis treatment.
Plasmapheresis in severe hypertriglyceridemia
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complications, such as sepsis, pancreatic necrosis, abscess for-
mation and renal insufﬁciency, or multiorgan dysfunction,
AP is considered a potential life-threatening illness with a
mortality rate of up to 7%–0% (2, 8). The diagnostic criteria
of AP require two of the following three features: character-
istic abdominal pain; serum amylase or lipase more than
three times the normal upper limit; ﬁndings of AP on CT
scan (10, 11). Our patients presented with all of these criteria.
However, in the setting of SHTG, amylase and lipase serum
levels may be normal or only mildly raised obscuring the cor-
rect diagnosis. It was important to exclude other diagnoses
for abdominal pain, such as cholecystitis, appendicitis, peptic
ulcer disease, and splenic or hepatic infarction, and other
causes for AP, namely, the presence of gallstones which was
not uncommon in patients with very high BMI, such as
ours. However, we cannot completely exclude this etiology.
For excluding that, it would be advisable to make a magnetic
resonance cholangiopancreatography (MRCP) to study the
bile and pancreatic ducts and to exclude the presence of
small stones. Although none of the patients had a MRCP
to exclude lithiasis, the abdominal CT did not show lithiasis
evidence and there was no analytical evidence of cholestasis.
The suggestive history of higher alcohol consumption in one
of our patients and the presence of SHTG in all of them
appeared to be the cause of AP.
Normal TG metabolism maintains safe levels lower than 150
mg/dl (12, 13). Excessive ingestion, excessive synthesis, or inef-
fective TG clearance leads to HTG. Therefore, the causes of
HTG may be categorized into primary disorders (genetically
based) such as lipoprotein lipase (LPL) and apolipoprotein
C-II deﬁciency, which are usually present in childhood as
chylomicronemia syndromes, and secondary disorders such
as obesity, untreated diabetes mellitus, alcoholism, pregnancy,
drugs associated (estrogens, glucocorticoids, and thiazide
diuretics) or lithiasis. Abnormalities of insulin responsiveness
are present in some of these cases (3, 14). The association of
SHTG and AP was ﬁrst postulated by Speck in 1865 (15).
SHTG is reported to account for up to 10% of all AP episodes
(16). It is generally believed that TG levels of >1000 mg/dl are
a greater risk factor for AP (3). This threshold is arbitrary and
the level above which AP might occur is actually unknown (4).
The exact pathophysiology still remains unclear. Several
mechanisms have been proposed, including the genetic pre-
disposition. The sheer size of TG can impede pancreatic
blood ﬂow and produce local acinar ischemia. The distur-
bance of the acinar structure liberates pancreatic lipase; this
enzyme degrades chylomicrons and there is a production of
pro-inﬂammatory free fatty acids. This pro-inﬂammatory
state plays a major role in the systemic responses to AP and
can accelerate pancreatic damage, producing local tissue
necrosis (12, 13). To remember, our patients have some risk
factors to HTG—those with type 2 diabetes, obesity, and
hypothyroidism have reduced LPL activity, although the
mechanism for this is unclear; therefore, the TG clearance
is reduced. Acute alcohol consumption has been shown to
increase plasma TG through twomechanisms: acute inhibition
of LPL and increased hepatic synthesis of Very-low-density
lipoprotein (VLDL).
The aim of the treatment is to reduce endogenous and exo-
genous sources of TG and promote their clearance. Exogen-
ous sources can be reduced by low-fat diets and fasting;
endogenous sources can be reduced by lipid-lowering medica-
tions and limited alcohol intake; clearance can be promoted
by insulin and heparin. Insulin activates LPL and heparin sti-
mulates the release of endothelial LPL into the circulation,
leading to an acceleration of chylomicron degradation. Life-
styles such as dietary changes, avoidance of alcohol, weight
reduction, exercise, and control of concomitant endocrinopa-
thy are imperative measures in the management of SHTG.
All of these measures take time, and in patients with SHTG
with hemodynamic instability or lack of response to medical
treatment, such as the cases reported here, there is an urgent
need of lowering the TG levels in order to prevent a multi‐
organ failure. PF consists in an extracorporeal separation
of blood components resulting in a ﬁltered plasma product,
and it has some clinical applications. In the setting of
SHTG, the goal is to remove the TG component of the
blood. But PF is a nonselective removal process; so it could
remove also circulating pro-inﬂammatory molecule stopping
the underlying inﬂammatory cascade. Its use for lowering TG
levels was ﬁrst reported in 1978 by Betteridge et al. (14).
Nowadays, experience with PF in acute hypertriglyceride-
induced pancreatitis is limited to case reports and case series,
and there are no consensus guidelines on optimal therapy.
Although rare, HTG is the cause of AP in pregnancy in 50%
of cases and, in these cases, there is a greater consensus regard-
ing its use because the use of ﬁbrates is not recommended.
Ewald et al. (15) showed that a single session of PF can
lower TG by 70%. Similarly, Yeh (16) reported that a single
cycle of PF lowered TG by 65% and a second cycle by 80%.
However, these authors did not ﬁnd any association between
the number of sessions and survival rates (4, 17, 18). In the
cases reported here, one or two sessions were sufﬁcient.
Ramirez et al. (17) described 11 patients submitted to PF—
in eight patients, a single plasma exchange was sufﬁcient to
reduce TG <1000 mg/dl. Only three patients died, all with
the worst severity indexes and who experienced most delay
before the procedure (19). The Clinical Practice Guidelines
recommend daily PF for 1–3 days depending on the patient
course and TG level (15, 20). The goal is to achieve TG con-
centrations lower than 500–1000 mg/dl. Heparin use as antic-
oagulant for the procedure may have advantages considering
its ability to release LPL, enhancing TG reduction (19).
Data suggest that PF should be performed as early as pos-
sible in order to achieve best results (21). Our patients under-
went PF in the ﬁrst 48 h after admission—they showed not
only a rapid reduction of TG but also a clinical improvement.
The ASFA (6) conducted a literature review to evaluate
the rationale use of PF in hypertriglyceridemic pancreatitis.
This review is consistent with the ﬁndings of Chen and
Campos A et al.
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Gubensek (19) and reported the absence of randomized con-
trolled trials about the effectiveness of the technique (9, 22).
However, there has been an increasing number of successful
cases described. It is also unclear whether PF increases hospi-
tal stay and/or mortality (22–24). Risks associated with PF
are low but they exist. The risk of infection may be better
weighed; PF does not selectively remove lipoproteins and
TG; coagulation factors and immunoglobulins are also
removed. Selective whole blood lipoprotein aphaeresis is fea-
sible in some centers without the undesired consequences of
PF, but it causes only a moderate reduction in TG levels (18).
Bleeding and catheter-associated complications may occur.
When 5% albumin is used, there is a progressive loss of coa-
gulation factors. Thus, the patient’s bleeding risk increases,
especially as the initial treatment requires intensive anticoa-
gulation to avoid system clotting. Hypersensitivity reactions
to fresh frozen plasma if used as a replacement ﬂuid have
been reported (16). There is no data recommending one repla-
cement ﬂuid over another. Most studies have used 5% albu-
min, while some have used fresh frozen plasma which
contains LPL; this could enhance TG removal (25, 26).
We have to consider that PF is an expensive technique that
is not available in all centers. Protocols should be created for
standardized clinical practice. We suggest that in AP due to
SHTG, PF should be performed concomitantly with medical
therapy in the ﬁrst 48 h after admission of patients with one or
more of the following severity criteria: Ranson score on
admission or in the ﬁrst 48 h greater than or equal to 3;
APACHE II score greater than 8, at any time; presence of
one or more organ failures; and presence of one or more
local complications. We suggest the use of 5% albumin repla-
cement solution or fresh frozen plasma if there are hemorrha-
gic complications, coagulation abnormalities, or severe
thrombocytopenia. PF should be performed until TG is less
than 500 mg/dl.
In conclusion, PF seems to be a relatively safe technique
that should be considered as a complementary treatment to
medical therapeutic in severe cases of acute hypertriglyceri-
demic pancreatitis, preferably in the early stages of the dis-
ease. A strictly pharmacologic treatment may be necessary
for the prevention of SHTG that leads to AP, but lifestyle
changes are also imperative.
Ideally, multicenter prospective studies should be con-
ducted in order to provide a sufﬁcient sample size in which
the patients could be randomized to receive either conven-
tional treatment or PF. However, it poses a big problem to
the clinicians—to give or not to give a treatment that quickly
removes the aggression trigger which may affect the patient
recovery and even survival. It would be important to establish
some guidelines for PF use, namely, the number of cycles that
are necessary and the timing in which the process should be
initiated. Maybe in the future, the process will be selective with
using membrane-coated antibodies at low costs. Although
rare, the complications of PF may contribute to morbidity
or even mortality, especially in the hemodynamically
compromised patients. We do not know whether there is an
improvement in mortality. However, we should consider
this technique if it is available in severe cases wherein the med-
ical therapy is not fast enough to prevent the inﬂammatory
cascade leading to multiorgan dysfunction.
Therefore, it is important to report all of similar cases to
ascertain the efﬁcacy, timing, and cost–beneﬁt ratio of PF
in the setting of AP due to SHTG. Maybe in the future, it
can be used as a ﬁrst-line therapy in selected cases as a bridge
to medical treatment.
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